HNF4A and MODY: In women with HNF4A MODY, serial growth assessment should be undertaken from 28 weeks, at 2‐weekly intervals at least, depending on growth trajectory, in addition to routine anomaly screening at earlier gestation as advised by the National Institute of Health and Care Excellence (NICE), to detect developing macrosomia in affected fetuses.